Alnylam Pharmaceuticals Total Assets 2006-2019 | ALNY

Alnylam Pharmaceuticals total assets from 2006 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Alnylam Pharmaceuticals total assets for the quarter ending March 31, 2019 were $2.014B, a 4.72% increase year-over-year.
  • Alnylam Pharmaceuticals total assets for 2018 were $1.575B, a 21.05% decline from 2017.
  • Alnylam Pharmaceuticals total assets for 2017 were $1.995B, a 57.96% increase from 2016.
  • Alnylam Pharmaceuticals total assets for 2016 were $1.263B, a 8.92% decline from 2015.
Alnylam Pharmaceuticals Annual Total Assets
(Millions of US $)
2018 $1,575
2017 $1,995
2016 $1,263
2015 $1,387
2014 $1,080
2013 $421
2012 $288
2011 $282
2010 $393
2009 $481
2008 $555
2007 $494
2006 $240
2005 $98
Alnylam Pharmaceuticals Quarterly Total Assets
(Millions of US $)
Q1 2019 $2,014
Q4 2018 $1,575
Q3 2018 $1,676
Q2 2018 $1,789
Q1 2018 $1,923
Q4 2017 $1,995
Q3 2017 $1,358
Q2 2017 $1,434
Q1 2017 $1,134
Q4 2016 $1,263
Q3 2016 $1,313
Q2 2016 $1,382
Q1 2016 $1,317
Q4 2015 $1,387
Q3 2015 $1,436
Q2 2015 $1,531
Q1 2015 $1,629
Q4 2014 $1,080
Q3 2014 $986
Q2 2014 $1,033
Q1 2014 $1,080
Q4 2013 $421
Q3 2013 $448
Q2 2013 $463
Q1 2013 $472
Q4 2012 $288
Q3 2012 $322
Q2 2012 $318
Q1 2012 $340
Q4 2011 $282
Q3 2011 $310
Q2 2011 $341
Q1 2011 $369
Q4 2010 $393
Q3 2010 $413
Q2 2010 $440
Q1 2010 $463
Q4 2009 $481
Q3 2009 $496
Q2 2009 $519
Q1 2009 $555
Q4 2008 $555
Q3 2008 $580
Q2 2008 $580
Q1 2008 $486
Q4 2007 $494
Q3 2007 $505
Q2 2007 $220
Q1 2007 $227
Q4 2006 $240
Q3 2006 $145
Q2 2006 $147
Q1 2006 $154
Q4 2005 $98
Q3 2005 $43
Q2 2005 $51
Q1 2005 $59
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.030B $0.075B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $108.806B 12.30
Gilead Sciences (GILD) United States $82.919B 10.07
Celgene (CELG) United States $63.614B 10.78
Biogen (BIIB) United States $44.842B 8.51
Vertex Pharmaceuticals (VRTX) United States $44.598B 53.91
Illumina (ILMN) United States $43.100B 49.95
CSL (CSLLY) Australia $35.794B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.576B 15.31
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.088B 15.33
Incyte (INCY) United States $17.271B 70.03
Exact Sciences (EXAS) United States $14.835B 0.00
BioMarin Pharmaceutical (BMRN) United States $14.607B 0.00
SINO PHARMACEUT (SBMFF) China $14.154B 0.00
Seattle Genetics (SGEN) United States $12.140B 0.00
Sarepta Therapeutics (SRPT) United States $11.068B 0.00
Genmab (GNMSF) Denmark $11.046B 56.15
Array BioPharma (ARRY) United States $10.373B 0.00
Galapagos (GLPG) Belgium $9.397B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $8.917B 29.29
Guardant Health (GH) United States $8.158B 0.00
Bio-Techne Corp (TECH) United States $7.933B 54.13
Bluebird Bio (BLUE) United States $7.614B 0.00
Exelixis (EXEL) United States $6.419B 16.36
Amarin (AMRN) Ireland $5.979B 0.00
BeiGene (BGNE) Cayman Islands $5.801B 0.00
Ascendis Pharma (ASND) Denmark $4.841B 0.00
Blueprint Medicines (BPMC) United States $4.775B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.762B 0.00
Moderna (MRNA) United States $4.642B 0.00
Horizon Pharma Public (HZNP) Ireland $4.456B 11.48
Repligen (RGEN) United States $4.099B 102.12
Mirati Therapeutics (MRTX) United States $3.821B 0.00
Spark Therapeutics (ONCE) United States $3.720B 0.00
ACADIA Pharmaceuticals (ACAD) United States $3.705B 0.00
China Biologic Products (CBPO) China $3.661B 23.25
Alkermes (ALKS) Ireland $3.651B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.569B 0.00
MorphoSys AG (MOR) Germany $3.528B 0.00
Arena Pharmaceuticals (ARNA) United States $3.064B 6.23
Amicus Therapeutics (FOLD) United States $2.934B 0.00
Immunomedics (IMMU) United States $2.860B 0.00
UniQure (QURE) Netherlands $2.736B 0.00
Medicines (MDCO) United States $2.670B 0.00
Reata Pharmaceuticals (RETA) United States $2.620B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.595B 0.00
MyoKardia (MYOK) United States $2.466B 0.00
Halozyme Therapeutics (HALO) United States $2.370B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $2.357B 0.00
NeoGenomics (NEO) United States $2.277B 149.06
Emergent Biosolutions (EBS) United States $2.269B 19.71
Ligand Pharmaceuticals (LGND) United States $2.233B 18.49
Acceleron Pharma (XLRN) United States $2.230B 0.00
Myriad Genetics (MYGN) United States $2.092B 20.81
Genomic Health (GHDX) United States $2.075B 44.07
Zai Lab (ZLAB) China $2.068B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.045B 0.00
Akcea Therapeutics (AKCA) United States $2.041B 0.00
Denali Therapeutics (DNLI) United States $1.988B 0.00
REGENXBIO (RGNX) United States $1.800B 0.00
Insmed (INSM) United States $1.720B 0.00
Cambrex (CBM) United States $1.514B 19.14
AnaptysBio (ANAB) United States $1.474B 0.00
RA PHARMCTL INC (RARX) United States $1.418B 0.00
Fate Therapeutics (FATE) United States $1.393B 0.00
Innoviva (INVA) United States $1.361B 3.76
Sangamo Therapeutics (SGMO) United States $1.338B 0.00
Alector (ALEC) United States $1.298B 0.00
Athenex (ATNX) United States $1.278B 0.00
Coherus BioSciences (CHRS) United States $1.226B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.185B 0.00
Editas Medicine (EDIT) United States $1.174B 0.00
Epizyme (EPZM) United States $1.156B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.032B 0.00
Cara Therapeutics (CARA) United States $1.030B 0.00
Codexis (CDXS) United States $1.011B 0.00
Twist Bioscience (TWST) United States $0.982B 0.00
ANI Pharmaceuticals (ANIP) United States $0.973B 17.25
Zymeworks (ZYME) Canada $0.952B 0.00
Momenta Pharmaceuticals (MNTA) United States $0.947B 0.00
Principia Biopharma (PRNB) United States $0.921B 0.00
Adverum Biotechnologies (ADVM) United States $0.891B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.884B 0.00
Retrophin (RTRX) United States $0.879B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Vericel (VCEL) United States $0.822B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.820B 0.00
WAVE Life Sciences (WVE) Singapore $0.794B 0.00
Arvinas (ARVN) United States $0.789B 0.00
Intellia Therapeutics (NTLA) United States $0.782B 0.00
Precision BioSciences (DTIL) United States $0.701B 0.00
Zealand Pharma (ZEAL) Denmark $0.692B 8.08
Vanda Pharmaceuticals (VNDA) United States $0.688B 32.47
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Intra-Cellular Therapies (ITCI) United States $0.652B 0.00
Cytokineticsorporated (CYTK) United States $0.643B 0.00
Cellectis S.A (CLLS) France $0.634B 0.00
Heska (HSKA) United States $0.622B 63.66
Autolus Therapeutics (AUTL) United Kingdom $0.612B 0.00
DBV Technologies S.A (DBVT) France $0.600B 0.00
Stemline Therapeutics (STML) United States $0.588B 0.00
Clovis Oncology (CLVS) United States $0.580B 0.00
Anika Therapeutics (ANIK) United States $0.577B 19.72
Lexicon Pharmaceuticals (LXRX) United States $0.561B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.560B 0.00
Revance Therapeutics (RVNC) United States $0.554B 0.00
CytomX Therapeutics (CTMX) United States $0.527B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
MiMedx (MDXG) United States $0.503B 0.00
Mesoblast (MESO) Australia $0.494B 0.00
PHARMA MAR SA (PHMMF) Spain $0.452B 0.00
UROGEN PHARMA (URGN) United States $0.438B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.437B 0.00
Puma Biotechnology (PBYI) United States $0.394B 0.00
Prothena (PRTA) Ireland $0.393B 0.00
AC Immune SA (ACIU) Switzerland $0.378B 24.35
PDL BioPharma (PDLI) United States $0.376B 8.97
Biofrontera AG (BFRA) Germany $0.373B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Arcus Biosciences (RCUS) United States $0.364B 0.00
Gritstone Oncology (GRTS) United States $0.361B 0.00
Starpharma Holdings (SPHRY) Australia $0.360B 0.00
Bellus Health (BLUSF) Canada $0.358B 0.00
Scholar Rock Holding (SRRK) United States $0.345B 0.00
Avid Bioservices (CDMO) United States $0.343B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.342B 0.00
Merus (MRUS) Netherlands $0.341B 0.00
BioDelivery Sciences (BDSI) United States $0.341B 0.00
Albireo Pharma (ALBO) United States $0.340B 0.00
Acorda Therapeutics (ACOR) United States $0.332B 5.85
Agenus (AGEN) United States $0.330B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.330B 0.00
Prometic Life Sciences (PFSCD) Canada $0.322B 0.00
Kadmon Holdings (KDMN) United States $0.321B 0.00
Theratechnologies (THERF) Canada $0.320B 0.00
Sorrento Therapeutics (SRNE) United States $0.319B 0.00
Syros Pharmaceuticals (SYRS) United States $0.314B 0.00
Protagonist Therapeutics (PTGX) United States $0.307B 0.00
Senesco Technologies (ELOX) United States $0.297B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.295B 0.00
Cellular Biomedicine (CBMG) United States $0.277B 0.00
Inovio Pharmaceuticals (INO) United States $0.274B 0.00
Kindred Biosciences (KIN) United States $0.264B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.258B 0.00
Sutro Biopharma (STRO) United States $0.256B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.246B 0.00
PHASEBIO PHARMA (PHAS) United States $0.246B 0.00
ChromaDex (CDXC) United States $0.245B 0.00
Kamada (KMDA) Israel $0.239B 9.28
Dynavax Technologies (DVAX) United States $0.238B 0.00
Geron (GERN) United States $0.229B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.225B 0.00
ADMA Biologics Inc (ADMA) United States $0.224B 0.00
Cel-Sci (CVM) United States $0.221B 0.00
CorMedix Inc (CRMD) United States $0.216B 0.00
Palatin Technologies (PTN) United States $0.215B 0.00
Athersys (ATHX) United States $0.213B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.202B 0.00
Five Prime Therapeutics (FPRX) United States $0.202B 0.00
MannKind (MNKD) United States $0.201B 0.00
Mersana Therapeutics (MRSN) United States $0.200B 0.00
Cerecor (CERC) United States $0.197B 0.00
Affimed (AFMD) Germany $0.193B 0.00
Pfenex (PFNX) United States $0.187B 0.00
OSMOTICA PHARM (OSMT) United States $0.184B 0.00
POXEL SA FRANCE (PXXLF) $0.184B 0.00
Abeona Therapeutics (ABEO) United States $0.184B 0.00
Synlogic (SYBX) United States $0.179B 0.00
Enzo Biochem (ENZ) United States $0.174B 0.00
Spero Therapeutics (SPRO) United States $0.174B 0.00
Compugen (CGEN) Israel $0.172B 0.00
Arsanis (XFOR) United States $0.168B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
XOMA (XOMA) United States $0.165B 0.00
BioTime (BTX) United States $0.165B 11.00
Nicox SA (NICXF) France $0.161B 0.00
Cue Biopharma (CUE) United States $0.157B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.156B 0.00
Strongbridge Biopharma (SBBP) United States $0.150B 8.66
Liquidia Technologies (LQDA) United States $0.144B 0.00
Celyad SA (CYAD) Belgium $0.142B 0.00
Alcobra (ARCT) United States $0.141B 0.00
OvaScience (MLND) United States $0.141B 0.00
Adocia (ADOCY) France $0.140B 0.00
Dyadic (DYAI) United States $0.136B 0.00
TOCAGEN INC (TOCA) United States $0.135B 0.00
Northwest Biotherapeutics (NWBO) United States $0.130B 0.00
Seres Therapeutics (MCRB) United States $0.127B 0.00
Aptinyx (APTX) United States $0.125B 0.00
NantKwest (NK) United States $0.121B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.114B 0.00
Aduro Biotech (ADRO) United States $0.114B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.110B 0.00
Novavax (NVAX) United States $0.108B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.108B 0.00
Verastem (VSTM) United States $0.106B 0.00
Checkpoint Therapeutics (CKPT) United States $0.104B 0.00
Menlo Therapeutics (MNLO) United States $0.103B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.103B 0.00
Catalyst Biosciences (CBIO) United States $0.099B 0.00
Arbutus Biopharma (ABUS) Canada $0.098B 0.00
SESEN BIO, INC (SESN) United States $0.098B 0.00
Trevena (TRVN) United States $0.094B 0.00
Fortress Biotech (FBIO) United States $0.089B 0.00
Pluristem Therapeutics (PSTI) Israel $0.088B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.087B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.084B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.082B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.080B 0.00
Unum Therapeutics (UMRX) United States $0.079B 0.00
VBI Vaccines (VBIV) United States $0.079B 0.00
AquaBounty Technologies (AQB) United States $0.078B 0.00
Curis (CRIS) United States $0.076B 0.00
Selecta Biosciences (SELB) United States $0.076B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.071B 0.00
Idera Pharmaceuticals (IDRA) United States $0.071B 0.00
Applied Genetic Technologies (AGTC) United States $0.071B 38.80
VTv Therapeutics (VTVT) United States $0.070B 0.00
Signal Genetics (MGEN) United States $0.070B 0.00
Orgenesis (ORGS) United States $0.067B 0.00
Oncobiologics (OTLK) United States $0.064B 0.00
Alimera Sciences (ALIM) United States $0.062B 0.00
Antibe Therapeutics (ATBPF) Canada $0.061B 0.00
ARAVIVE, INC (ARAV) United States $0.060B 0.00
NewLink Genetics (NLNK) United States $0.060B 0.00
Organovo Holdings (ONVO) United States $0.060B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.058B 0.00
Protalix BioTherapeutics (PLX) Israel $0.058B 0.00
Prima BioMed (IMMP) Australia $0.057B 0.00